Measles-Mumps-Rubella Vaccine

ApprovedVaccine

LLiaoning Chengda Biotechnology CO., LTD

Measles-Mumps-Rubella Vaccine is one of 50 biologic programs targeting Japanese encephalitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

AllergyActive, not recruiting

Japanese EncephalitisApproved

Active, not recruiting

AllergyApproved

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Allergy

#DrugCompanyPhaseTrials

Flovent

GSK

Phase 3

1 2

Clarinex

OOrganon and Co

Phase 3

1 3

Xolair

Roche

Phase 2

7 4

REGN5715

Regeneron

Phase 3

1 5

REGN5713

Regeneron

Phase 3

1 6

Rhapsido

Novartis

Phase 2

1 7

Ligelizumab

Novartis

Phase 3

1 8

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

3 9

Measles-Mumps-Rubella Vaccine

LLiaoning Chengda Biotechnology CO., LTD

Approved

1 10

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Allergy

NCT05758532

Clinical

Trials by Indication[1]

Japanese encephalitis2 trials

Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine

Completed·PPATH·Phase 4·NCT02880865·628 enrolled

Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

Completed·LLiaoning Chengda Biotechnology CO., LTD·Phase 4·NCT06331702·408 enrolled

Rotavirus Vaccine1 trial

The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine

Unknown status·SSichuan Center for Disease Control and Prevention·Phase 4·NCT02153866·2,800 enrolled

Immunization1 trial

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00013871·300 enrolled

Allergy1 trial

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

Recruiting·LLaure Pittet, MD-PhD·Phase 4·NCT05758532·500 enrolled

MMR Vaccine1 trial

A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts

Completed·—·N/A·NCT04428359·66 enrolled

2 more indications

Cryotherapy1 trial

Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

Completed·—·Phase 4·NCT03183765·48 enrolled

Measles Vaccine1 trial

Measles Vaccine in HCW

Suspended·KKasr El Aini Hospital·Phase 3·NCT04357028·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Measles-Mumps-Rubella Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Measles-Mumps-Rubella Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Measles-Mumps-Rubella Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liaoning Chengda Biotechnology CO., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: LLiaoning Chengda Biotechnology CO., LTD

Measles-Mumps-Rubella Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Japanese encephalitis2 trials

Rotavirus Vaccine1 trial

Immunization1 trial

Allergy1 trial

MMR Vaccine1 trial

Cryotherapy1 trial

Measles Vaccine1 trial

References

Drug Info

Quick Facts

Related News